Skip to main content

Table 1 Characteristics of subjects

From: Beneficial association of angiotensin-converting enzyme inhibitors and statins on the occurrence of possible Alzheimer’s disease after traumatic brain injury

  Possible AD Non-AD
A. Analysis of association of TBI with development of dementia with possible AD
 Age 80.9 ± 6.7 70.1 ± 10.1
 Sex
  Male 62,951 556,525
  Female 1388 31,920
 Ethnicity
  Caucasian 51,884 445,237
  African American 6779 97,782
  Hispanic 4565 30,581
  Other 1111 14,845
B. Analysis of association of medications with development of dementia with possible AD after TBI occurrence
 Age 76.9 ± 8.5 64.5 ± 9.8
 Sex
  Male 310 5663
  Female 17 710
 Ethnicity
  White 228 4431
  African American 35 1243
  Hispanic 57 506
  Other 7 193
 Medication
  No med 92 1957
  ACEI 47 644
  Beta blocker 35 868
  Metformin 29 403
  Statin 57 1105
  ACEI + beta blocker 15 262
  ACEI + metformin 2 133
  ACEI + statin 14 359
  Beta blocker + statin 21 394
  Beta blocker + metformin 3 89
  Metformin + statin 12 159
  1. Note: “Medication” designates single and combination patterns of the four target medication classes. Subjects who were prescribed medications other than the target medication classes in the dataset are included as “No med” group. Subjects who were on any of those medication classes at the start of study window or were prescribed three or four of those classes are excluded